In conclusion, these clinical and mechanistic findings identified a novel CD63‐IL‐6/IL‐27‐STAT3 axis in HCC tumorigenesis and development, and targeting this axis is a potential therapeutic strategy against HCC. This evidence concerns the gene CD63 and hepatocellular carcinoma.